Fiche centre
VCU Massey Comprehensive Cancer Center
Richmond — United States
Essais liés21clinical trials
VilleRichmondlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03984448
Essais cliniques associés
21| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Biospecimen Collection | Cancer | Phase 2 | NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | RECRUITING |
| Biospecimen Collection | SEP | Phase 3 | NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | ACTIVE_NOT_RECRUITING |
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING |
| Biospecimen Collection | SEP | Phase 2/3 | NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING |
| Biopsy Procedure | Cancer | Phase 1 | NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | RECRUITING |
| Biopsy Procedure | Cancer | Phase 2 | NCT06064097 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | RECRUITING |
| Biopsy Procedure | Cancer | Phase 1/2 | NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Bone Scan | Cancer | Phase 2/3 | NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | SUSPENDED |
| Biopsy Procedure | Cancer | Phase 2 | NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Biospecimen Collection | Cancer | Non applicable | NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | RECRUITING |
| Biospecimen Collection | Lupus | Phase 1 | NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING |
| Biopsy Procedure | Cancer | Phase 2 | NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | RECRUITING |
| silevertinib in combination with temozolomide | Cancer | Phase 2 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | RECRUITING |
| Biospecimen Collection | Cancer | Phase 2/3 | NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | RECRUITING |